Two nonstatin cholesterol-lowering drugs are PCSK9 inhibitors. They include evolucumab (Repatha) and alirocumab (Praluent). They are injected once or twice a month. Side effects of Repatha may include ...

Praluent is a prescription drug used for certain conditions, including high cholesterol. Find out about possible interactions ...

QUESTION: Watch out for serious drug interactions with Preparation H! A few years ago, I was taking a beta blocker drug ...

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...

Two non-statin cholesterol-lowering drugs are PCSK9 inhibitors. They include evolucumab (Repatha) and alirocumab (Praluent).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 ...

Highlighted text has been updated as of November 7, 2024. The PACMAN-AMI trial showed that, compared with placebo, administration of alirocumab 150 mg biweekly within 24 hours after PCI for AMI ...

The reported number represents a year-over-year change of +6.1%. Revenues- Praluent (alirocumab)- US: $52.90 million compared to the $43.25 million average estimate based on five analysts.

TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.